Clinical trials and equitable care pathways are needed to build on early evidence of benefit Substance use disorders (SUDs) are common and burdensome for patients, families, and health systems,12 yet ...

Where do indications for GLP-1 receptor agonists (RAs) currently stand? Experts addressed these questions at the French Nutrition Days 2025 in Lyon, France, with a focus on obesity treatment, ...

Phenomix's MyPhenome test continues to demonstrate predictive accuracy in identifying which patients are most likely to respond to GLP-1 therapies such as semaglutide. Studies presented at Obesity ...

People struggling with many addictions, ranging from opioids to gambling, are reporting similar experiences in clinics, on social media and around dinner tables.

Dec 23 (Reuters) - The U.S. Centers for Medicare and Medicaid Services on Tuesday unveiled a voluntary program to cover GLP-1 drugs for weight-loss and diabetes under Medicaid and Medicare Part D ...

A November 2025 Kaiser Family Foundation poll found that 1 in 8 U.S. adults have tried a GLP-1 medication for weight loss, diabetes or another condition. And we expect that number to rise now that one ...

Kristen Fischer has written for numerous health publications, hospitals, and medical companies, and is a member of the Association of Health Care Journalists. Nick Blackmer is a librarian, ...

McDonald’s signaled this week it’s looking to better cater to customers on weight-loss drugs — and the name of the game is protein. During a Wednesday earnings call, McDonald’s CEO Chris Kempczinski ...

Jess Loren remembers loving the taste of Cap'n Crunch cereal. Coca-Cola. Snickers bars. But now, instead of a sweetness, "they taste bland," she says. Flavors are noticeably muted since she started a ...

Weight-loss pills that harness the same mechanism as the wildly popular drugs Wegovy and Ozempic are coming to the U.S. On Monday Novo Nordisk announced that the U.S. Food and Drug Administration ...